Funding
← Back to your selection

Eli Lilly and Company

Activity from announced rounds

Activity in this selectionSeries B

Eli Lilly and Company is a medicines developer that also finances external innovation and provides laboratory and development resources to early biotechnology companies.

Its Catalyze360 platform combines several ways to work with a startup. Lilly Ventures provides investment; Lilly Gateway Labs provides laboratory facilities and scientific engagement; Lilly ExploR&D provides research and development capabilities.

The platform engages biotechs at the earliest stages across therapeutic areas. Its investment remit extends into new scientific platforms and health technology, giving founders routes to strategic capital and development infrastructure through different parts of Lilly’s external innovation organisation.

Sources
Rounds participated in
7
Confirmed lead rounds
0
3 roles undisclosed
New companies
7
First participation on record · 0 follow-on
Funding in participating rounds
$463.5M
7 disclosed · full round size, not this investor’s share

By stage

Series B7

By primary sector

Biotech6
Healthtech1

By country

United States7

Rounds

7 in this selection
General Medicine

An online healthcare store where people compare care options and upfront prices, book visits and order medications or lab tests.

$120MSeries B
Participant
Moonwalk Biosciences

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

$70MSeries B
Participant
Superluminal Medicines

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

$60MSeries B
Participant
Amplifica Holdings Group

Amplifica develops injectable drug candidates intended to reactivate hair follicles in people with androgenetic alopecia.

$26MSeries B
Participant
InduPro

Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease

$77MSeries B
Role not disclosed